Impact of β2-Adrenoceptor Haplotype on Asthma Treatment Responses
Author Information
Author(s): Anneke van Veen, Eddy A Wierenga, Robert Westland, Frank R Weller, Guus AM Hart, Henk M Jansen, René E Jonkers
Primary Institution: Academic Medical Centre, University of Amsterdam
Hypothesis
The study aimed to evaluate the impact of β2-adrenoceptor haplotypes on β2-agonist mediated airway responses and the development of tolerance in mild to moderate asthmatics.
Conclusion
Differences exist between β2-adrenoceptor genotypes in airway responses and tolerance development, but these differences are unlikely to be clinically significant.
Supporting Evidence
- Three limited allelic haplotypes were identified among the patients.
- Statistically significant differences in PD20 methacholine responses were observed based on genotype.
- Terbutaline pre-treatment significantly reduced PD20 compared to placebo.
Takeaway
The study looked at how different genetic types affect asthma treatment responses, finding some differences, but they probably don't matter much in real life.
Methodology
Patients were genotyped and underwent a double-blind, randomized, cross-over study with terbutaline or placebo, measuring responses to fenoterol and methacholine.
Limitations
The study used a small sample size and focused on short-acting β2-agonists, which may limit the generalizability of the findings.
Participant Demographics
45 asthmatic patients (11 male, 34 female) with a mean FEV1 of 84.6% predicted.
Statistical Information
P-Value
0.0029
Confidence Interval
31–68%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website